Star Update Podcast - Cardiology News Summaries

Ticagrelor monotherapy in ST-elevation myocardial infarction: An individual patient-level meta-analysis from TICO and T-PASS trials Med. 2024 Aug 10:S2666-6340(24)00301-5. doi: 10.1016/j.medj.2024.07.019.  Abstract Background: Patients with ST-elevation myocardial infarction (STEMI) tend to be excluded or under-represented in randomized clinical trials evaluating the effects of potent P2Y12 inhibi...

Non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting: a meta-analysis of invasive vs. conservative management Eur Heart J . 2024 Jul 12;45(27):2380-2391. doi: 10.1093/eurheartj/ehae245   Abstract Background and aims : A routine invasive strategy is recommended in the management of higher risk patients with non-ST-elevation acute coronary syndromes (NSTE-ACSs). Ho...

Verification of haemoglobin level to prevent worsening of prognosis in heart failure with preserved ejection fraction patients from the PURSUIT-HFpEF registry https://doi.org/10.1002/ehf2.14927  Abstract Aim Anaemia has been reported as poor predictor in heart failure with preserved ejection fraction (HFpEF). The aim of this study was to evaluate the impact of changes in haemoglobin (Hb) from disc...

Ticagrelor downregulates the expression of proatherogenic and proinflammatory micro RNA 125-b compared to clopidogrel: A randomized, controlled trial Int J Cardiol . 2024 Jul 1:406:132073   Abstract Background: Platelet P2Y12 antagonist ticagrelor reduces cardiovascular mortality after acute myocardial infarction (AMI) compared to clopidogrel, but the underlying mechanism is unknown. Because activ...

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy Clin Pharmacol Ther. 2024 Jul 1. doi: 10.1002/cpt.3351   Abstract Beta-blockers are widely used medications for a variety of indications, including heart failure, myocardial infarction, cardiac arrhythmias, and hypertension. Genetic variability in...

Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial Am Heart J. 2024 Jun:272:11-22. doi: 10.1016/j.ahj.2024.03.002   Abstract Background: The optimal antiplatelet regimen after percutaneous coronary intervention (PCI) in patients with periphera...

 Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised Different Antiplatelet Therapy Strategy   After Coronary Artery Bypass Grafting  trial BMJ . 2024 Jun 11:385:e075707. doi: 10.1136/bmj-2023-075707.   Abstract Objective: To assess the effect of different antiplatelet strategies on clinical outcomes after coronary artery bypass grafting.   Design : Five ye...

Coronary Atherosclerotic Plaque Activity and Risk of Myocardial Infarction J Am Coll Cardiol. 2024 Jun 4;83(22):2135-2144   Abstract Background: Total coronary atherosclerotic plaque activity across the entire coronary arterial tree is associated with patient-level clinical outcomes.   Objectives: We aimed to investigate whether vessel-level coronary atherosclerotic plaque activity is associated w...

The new ESC acute coronary syndrome guideline and its impact in the CPU and emergency department setting Herz. 2024 Jun;49(3):185-189. doi: 10.1007/s00059-024-05241-6   The new guideline on acute coronary syndrome (ACS) of the European Society of Cardiology (ESC) replaces two separate guidelines on ST-elevation myocardial infarction (STEMI) and non-ST-elevation (NSTE) ACS  . This change of paradig...

Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomized, placebo-controlled, double-blind clinical trial Randomized Controlled Trial Lancet . 2024 May 11;403(10439):1866-1878. doi: 10.1016/S0140-6736(24)00473-2.   Abstract Background: Following percutaneous coronary int...

Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: A systematic review and meta-analysis  Int J Cardiol . 2024 May 1:402:131813. doi: 10.1016/j.ijcard.2024.131813   Abstract Objective: This systematic review aimed to assess the tolerability of patients with cardiac amyloidosis (CA) to beta-blockers (BBs) and evaluate its association with adverse outcomes.   Metho...

Management of Severe Mitral Regurgitation in Patients With Acute Myocardial Infarction: JACC Focus Seminar 2/5 J Am Coll Cardiol . 2024 May 7;83(18):1799-1817. doi: 10.1016/j.jacc.2023.09.840   Abstract Severe acute mitral regurgitation after myocardial infarction includes partial and complete papillary muscle rupture or functional mitral regurgitation. Although its incidence is <1%, mitral reg...

Obesity is associated with acute kidney injury in ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention: A national representative cohort study Catheter Cardiovasc Interv . 2024 May;103(6):897-908. doi: 10.1002/ccd.31030 Abstract Background: Acute kidney injury (AKI) is a frequent and potentially life-threatening complication after percutaneous coronary intervent...

Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention J Endocrinol Invest. 2024 Apr;47(4):895-902. doi: 10.1007/s40618-023-02205-1 Abstract Purpose: Patients with coronary artery disease have increased fracture risks. P2Y12 inhibitors may impact fracture risks...

Prognostic Impact of Early Administration of β-Blockers in Critically Ill Patients with Acute Myocardial Infarction J Clin Pharmacol . 2024 Apr;64(4):410-417. doi: 10.1002/jcph.2370.   Abstract In critically ill patients with acute myocardial infarction (AMI), the relationship between the early administration of β-blockers and the risks of in-hospital and long-term mortality remains controversial....

Impact of cardiac rehabilitation on ventricular-arterial coupling and left ventricular function in patients with acute myocardial infarction PLoS One . 2024 Apr 4;19(4):e0300578. doi: 10.1371/journal.pone.0300578 Abstract To maintain efficient myocardial function, optimal coordination between ventricular contraction and the arterial system is required. Exercise-based cardiac rehabilitation (CR) ha...

 The application value of Metoprolol combined with Dagalizin in enhancing cardiac function and ventricular remodeling in patients with acute myocardial infarction after percutaneous coronary intervention. J Clin Emerg, 2024, 25(4): 170-174. doi: 10.13201/j.issn.1009-5918.2024.04.003 Abstract To discuss the application value of metoprolol combined with daglizin in improving cardiac function and ven...

The efficacy and safety of aspirin-ticagrelor vs. aspirin-clopidogrel in ischemic stroke patients with cerebral artery stenting Clin Neurol Neurosurg . 2024 Mar 3:239:108229.  Abstract Objective : First, the efficacy and safety of aspirin-ticagrelor after cerebral artery stenting in ischemic stroke patients is controversial. Second, there is a gap in the research on guiding two antiplatelet therap...

Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis    Curr Probl Cardiol. 2024 Mar;49(3):102376  Abstract Introduction: While beta-blockers are considered the cornerstone of treatment for heart failure with reduced ejection fraction, the same may not apply to patients with heart failure with preserved ejection fraction. To date,...

P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial JAMA Netw Open. 2024 Mar 4;7(3):e240877  Abstract Importance: P2Y12 inhibitor monotherapy after dual antiplatelet therapy (DAPT; a P2Y12 inhibitor plus aspirin) for a brief duration has recently emerged as an attractive alternative for patients undergoing percutane...

Myocardial infarction drives trained immunity of monocytes, accelerating atherosclerosis Eur Heart J . 2024 Mar 1;45(9):669-684.  Abstract Background and aims : Survivors of acute coronary syndromes face an elevated risk of recurrent atherosclerosis-related vascular events despite advanced medical treatments. The underlying causes remain unclear. This study aims to investigate whether myocardial i...

2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2024;Mar 8:[Epub ahead of print].       In line with recent evidence and guidelines, the recommended core guideline-directed medical therapy (GDMT) for chronic heart failure (HF) includes an angi...

Ticagrelor versus Clopidogrel in Endovascular therapy for Cerebral Aneurysms: A Systematic Review and Meta-analysis   World Neurosurg . 2024 Feb 9:S1878-8750(24)00210-9  Abstract Background: Antiplatelet therapy is pivotal in endovascular treatment for intracranial aneurysms. However, there is a lack of studies comparing ticagrelor to clopidogrel in patients with aneurysms undergoing endovascular...

 Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guideline    Am J Med . 2024 Feb;137(2):137-146.e10. doi:10.1016/j.amjmed.2023.09.021 Abstract Objective: We aimed to evaluate the applicability of the eligibility criteria of randomized controlled trials (RCTs) cited in guideline recommendation...

Factors Associated With Myocardial Infarction in a Rural Population With Peripheral Arterial Diseases Angiology. 2024 Feb 6:33197241232608. doi: 10.1177/00033197241232608. Abstract Peripheral arterial disease (PAD) studies in rural populations are limited. The incidence of myocardial infarction (MI) is higher in patients with PAD. This study examined the association between sociodemographic and cl...